HomeJAZZ • NASDAQ
Jazz Pharmaceuticals PLC
$121.01
Mar 28, 1:24:09 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$120.51
Day range
$120.03 - $121.19
Year range
$111.25 - $147.98
Market cap
7.55B USD
Avg Volume
738.08K
P/E ratio
19.83
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
1.01B4.10%
Operating expense
702.50M15.49%
Net income
94.15M139.11%
Net profit margin
9.30137.56%
Earnings per share
5.027,271.43%
EBITDA
393.75M-4.30%
Effective tax rate
-54.19%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
1.63B84.93%
Total assets
11.39B5.15%
Total liabilities
7.66B-1.20%
Total equity
3.74B
Shares outstanding
62.35M
Price to book
2.01
Return on assets
5.19%
Return on capital
6.23%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
94.15M139.11%
Cash from operations
167.34M-51.07%
Cash from investing
101.80M131.38%
Cash from financing
-100.31M-611.87%
Net change in cash
170.62M305.04%
Free cash flow
81.77M1,714.96%
About
Jazz Pharmaceuticals plc is an American biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Founded
Mar 2005
Employees
2,800
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu